Altoida is a health technology firm that uses digital biomarkers to drive better clinical outcomes for brain diseases. Led by a team of esteemed neuroscientists, physicians and computer scientists, the company offers a FDA and CE Mark-cleared medical device and brain health data platform to support early detection of Alzheimer’s disease up to ten years prior to onset – with up to 94% accuracy. The company is headquartered in Houston, TX, and has offices in San Diego, CA, and Lucerne, Switzerland.

Team Member
more about
Alexander Hoffmann
Latest News Entry
Altoida raises $6.3m Series A to Predict Alzheimer’s Disease Risk Using Artificial Intelligence, Machine Learning and Augmented Reality

New digital biomarkers company secures $6.3 MM in venture capital to detect Alzheimer’s disease 6-10 years prior to onset of Mild Cognitive Impairment (MCI) symptoms - with up to 94% accuracy

all portfolio news